Reiki Nishimura

17.8k total citations · 1 hit paper
131 papers, 13.3k citations indexed

About

Reiki Nishimura is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Reiki Nishimura has authored 131 papers receiving a total of 13.3k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Oncology, 62 papers in Cancer Research and 32 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Reiki Nishimura's work include Breast Cancer Treatment Studies (57 papers), HER2/EGFR in Cancer Research (55 papers) and Cancer Treatment and Pharmacology (35 papers). Reiki Nishimura is often cited by papers focused on Breast Cancer Treatment Studies (57 papers), HER2/EGFR in Cancer Research (55 papers) and Cancer Treatment and Pharmacology (35 papers). Reiki Nishimura collaborates with scholars based in Japan, United States and Switzerland. Reiki Nishimura's co-authors include Nobuyuki Arima, Tomofumi Osako, Yasuo Toyozumi, Rumiko Tashima, Yasuyuki Nishiyama, Mamiko Fujisue, Masahiro Nakano, Yasuhiro Okumura, Mitsuhiro Hayashi and Haruhiko Miyayama and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Reiki Nishimura

124 papers receiving 13.2k citations

Hit Papers

Evaluation of Factors Related to Late Recurrence - Later ... 2013 2026 2017 2021 2013 2.5k 5.0k 7.5k 10.0k

Peers

Reiki Nishimura
Reiki Nishimura
Citations per year, relative to Reiki Nishimura Reiki Nishimura (= 1×) peers Nobuyuki Arima

Countries citing papers authored by Reiki Nishimura

Since Specialization
Citations

This map shows the geographic impact of Reiki Nishimura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reiki Nishimura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reiki Nishimura more than expected).

Fields of papers citing papers by Reiki Nishimura

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reiki Nishimura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reiki Nishimura. The network helps show where Reiki Nishimura may publish in the future.

Co-authorship network of co-authors of Reiki Nishimura

This figure shows the co-authorship network connecting the top 25 collaborators of Reiki Nishimura. A scholar is included among the top collaborators of Reiki Nishimura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reiki Nishimura. Reiki Nishimura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Misumi, Ikuo, et al.. (2024). Delayed Trastuzumab-induced Cardiotoxicity Leading to Severe Left Ventricular Dysfunction. Internal Medicine. 64(12). 1849–1857.
2.
Nishimura, Reiki, Tetsuhiko Taira, Toshiko Miyaki, et al.. (2024). The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes. Clinical Breast Cancer. 24(5). 431–438. 2 indexed citations
3.
Takashima, Tsutomu, Fumikata Hara, Takayuki Iwamoto, et al.. (2021). A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study. Clinical Breast Cancer. 21(5). 450–457. 1 indexed citations
4.
Mukai, Hirofumi, Takeshi Yamaguchi, Masato Takahashi, et al.. (2020). Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study. British Journal of Cancer. 122(12). 1747–1753. 13 indexed citations
5.
Yamaguchi, Takeshi, Yasuo Hozumi, Yasuaki Sagara, et al.. (2020). The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial. Surgical Oncology. 36. 51–55. 5 indexed citations
6.
Ohno, Shinji, Hirofumi Mukai, Kazutaka Narui, et al.. (2019). Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study. Breast Cancer Research and Treatment. 176(3). 631–635. 4 indexed citations
7.
Nakano, Masahiro, Mamiko Fujisue, Rumiko Tashima, et al.. (2015). Survival time according to the year of recurrence and subtype in recurrent breast cancer. The Breast. 24(5). 588–593. 14 indexed citations
8.
Arima, Nobuyuki, Reiki Nishimura, Tomofumi Osako, et al.. (2015). A Comparison of the Hot Spot and the Average Cancer Cell Counting Methods and the Optimal Cutoff Point of the Ki-67 Index for Luminal Type Breast Cancer. Oncology. 90(1). 43–50. 13 indexed citations
9.
Nishimura, Reiki, Tomofumi Osako, Yasuhiro Okumura, et al.. (2013). Definition of p53 overexpression and its association with the clinicopathological features in luminal/HER2-negative breast cancer.. PubMed. 33(9). 3891–7. 30 indexed citations
10.
Nishiyama, Yasuyuki, et al.. (2013). A Case of Recurrent Metastasis in the Supraclavicular and Axillary Lymph Nodes and Vertebrae following Irradiation and Paclitaxel Plus Bevacizumab Administration. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 74(8). 2081–2084.
11.
Kubo, Makoto, Noriko Kanaya, Jingjing Ye, et al.. (2012). Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Breast Cancer Research and Treatment. 137(1). 93–107. 44 indexed citations
12.
Nishimura, Reiki, Tomofumi Osako, Yasuhiro Okumura, et al.. (2011). Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World Journal of Surgical Oncology. 9(1). 131–131. 84 indexed citations
13.
Nishimura, Reiki & Nobuyuki Arima. (2008). Is triple negative a prognostic factor in breast cancer?. Breast Cancer. 15(4). 303–308. 83 indexed citations
15.
Nishimura, Reiki, Yasuhiro Okumura, & Nobuyuki Arima. (2007). Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Breast Cancer. 15(1). 57–64. 31 indexed citations
16.
Miyayama, Haruhiko, et al.. (2004). Intraoperative cytologic diagnosis of sentinel lymph node metastasis in breast cancer-Combination of imprint cytology and immunocytochemistry-. The Journal of the Japanese Society of Clinical Cytology. 43(6). 363–369. 2 indexed citations
17.
Nishimura, Reiki, Fujio Kasumi, Kansei Komaki, et al.. (1998). A Case Control Study on Risk Factors Involved in Inflammatory Breast Recurrence afterBreast-Conserving Surgery. Oncology. 55(5). 391–399. 9 indexed citations
18.
Matsuda, Masakazu, et al.. (1989). A case of primary early carcinoma of duodenum.. The Japanese Journal of Gastroenterological Surgery. 22(12). 2841–2844. 3 indexed citations
19.
Kawano, Ichiro, et al.. (1987). A case report polypoid cancer of the sigmoid colon associated with rectosigmoid intussusception.. The Japanese Journal of Gastroenterological Surgery. 20(8). 2011–2014.
20.
Hosaka, Masami, et al.. (1973). Radioimmunoassay for plasma testosterone. OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information). 136. 104720–104720. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026